Search - tctmd.com

Displaying 1 - 20 of 39

Sort: Relevancy | Date

‘Investing’ in CTOs With Staged PCI Seems to Pay Off in Safety Gains

News Conference News TCT 2025

‘Investing’ in CTOs With Staged PCI Seems to Pay Off in Safety Gains

Yael L. Maxwell

November 05, 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

News Conference News TCT 2025

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

October 27, 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

October 27, 2025

Tendyne Safely Reduces MR in Patients With Severe Calcification: SUMMIT-MAC

News Conference News TCT 2025

Tendyne Safely Reduces MR in Patients With Severe Calcification: SUMMIT-MAC

Yael L. Maxwell

October 27, 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

Trials Bolster Alternatives to Intravascular Lithotripsy for Calcified Lesions

News Conference News TCT 2025

Trials Bolster Alternatives to Intravascular Lithotripsy for Calcified Lesions

October 26, 2025

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

October 29, 2024

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

News Conference News TCT 2023

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

Michael O'Riordan

November 01, 2023

SUMMIT: MV Replacement With Tendyne Shows Promise in Severe MR, MAC

News Conference News TCT 2023

SUMMIT: MV Replacement With Tendyne Shows Promise in Severe MR, MAC

Yael L. Maxwell

October 30, 2023

Disrupt CAD III Shows Sustained Benefit for Lithotripsy at 1 Year

News Conference News TCT 2021

Disrupt CAD III Shows Sustained Benefit for Lithotripsy at 1 Year

November 05, 2021

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

News Conference News TCT 2021

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

Michael O'Riordan

November 05, 2021

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

News Conference News TCT 2021

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

Michael O'Riordan

November 04, 2021

De-escalating Prasugrel Reduces Net Events in Complex PCI for ACS

News Conference News TCT 2021

De-escalating Prasugrel Reduces Net Events in Complex PCI for ACS

Yael L. Maxwell

October 22, 2021

Acurate Neo Still Falls Short of Sapien 3 in SCOPE 1-Year Follow-up

News Conference News TCT 2020

Acurate Neo Still Falls Short of Sapien 3 in SCOPE 1-Year Follow-up

Michael O'Riordan

October 23, 2020

Direct Temsirolimus Delivery Shows Promise in BTK: Phase II Study

News Conference News TCT 2020

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

October 18, 2020

Sapien 3 Stroke Rate Perplexes in 1-Year SOLVE-TAVI Results

News Conference News TCT 2020

Sapien 3 Stroke Rate Perplexes in 1-Year SOLVE-TAVI Results

Michael O'Riordan

October 16, 2020

Large Databases Hint at Sentinel Benefit During TAVR, but Uncertainty Remains

News Conference News TCT 2020

Large Databases Hint at Sentinel Benefit During TAVR, but Uncertainty Remains

October 16, 2020

DISRUPT CAD III: Lithotripsy Boosts Stent Expansion in Highly Calcified Lesions

News Conference News TCT 2020

DISRUPT CAD III: Lithotripsy Boosts Stent Expansion in Highly Calcified Lesions

October 15, 2020

Intravascular Lithotripsy Shows Good Safety at 30 Days: DISRUPT CAD II

News Conference News TCT 2019

Intravascular Lithotripsy Shows Good Safety at 30 Days: DISRUPT CAD II

Yael L. Maxwell

October 08, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.